View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNuvalent 過去の業績過去 基準チェック /06Nuvalentの収益は年平均-49.5%で減少しているが、Biotechs業界はgrowingで13.4%年平均の収益となった。主要情報-49.51%収益成長率-2.85%EPS成長率Biotechs 業界の成長-14.59%収益成長率n/a株主資本利益率-38.32%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.お知らせ • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.お知らせ • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.収支内訳Nuvalent の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:5AX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-45012331631 Dec 250-42510730730 Sep 250-3819030930 Jun 250-3437728531 Mar 250-3016925431 Dec 240-2616321830 Sep 240-2245718430 Jun 240-1745015331 Mar 240-1464213031 Dec 230-1263611330 Sep 230-1143210130 Jun 230-100288631 Mar 230-89257331 Dec 220-82226430 Sep 220-73205430 Jun 220-66184931 Mar 220-57154331 Dec 210-46103630 Sep 210-3672730 Jun 210-2842231 Mar 210-2721831 Dec 200-15215質の高い収益: 5AXは現在利益が出ていません。利益率の向上: 5AXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 5AXは利益が出ておらず、過去 5 年間で損失は年間49.5%の割合で増加しています。成長の加速: 5AXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 5AXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。株主資本利益率高いROE: 5AXは現在利益が出ていないため、自己資本利益率 ( -38.32% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 05:46終値2026/07/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nuvalent, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Colleen KusyBairdEtzer DaroutBarclaysJeffrey WalchBernstein21 その他のアナリストを表示
お知らせ • Jul 17Nuvalent, Inc. Announces Board and Committee ChangesAs previously disclosed in the Current Report on Form 8-K filed on June 9, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) by Nuvalent, Inc., a Delaware corporation (the “Company”), on June 9, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“Ultimate Parent”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (James R. Porter, Ph.D.; Grant C. Bogle; Michael L. Meyers, M.D., Ph.D.; Christy Oliger; Anna Protopapas; Ron Squarer; Sapna Srivastava, Ph.D.; and Cameron A. Wheeler, Ph.D.) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Justin T. Huang and Kevin T. Ryan, the directors of Purchaser immediately prior to the Effective Time, became the directors of the Company as the surviving corporation. As of the Effective Time, in accordance with the Merger Agreement, the officers of Purchaser immediately prior to the Effective Time became the officers of the Company as the surviving corporation. The officers of the Company as the surviving corporation as of the Effective Time are as follows: Justin T. Huang as President and Secretary, Kevin T. Ryan as Vice President and Treasurer, and Hatixhe Hoxha as Assistant Secretary. Biographical and other information with respect to Justin T. Huang, Kevin T. Ryan and Hatixhe Hoxha is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO filed with the SEC by Parent on June 24, 2026 and is incorporated herein by reference.
お知らせ • Jul 16Nuvalent, Inc.(NasdaqGS:NUVL) dropped from NASDAQ Biotechnology IndexNuvalent, Inc. has been dropped from the NASDAQ Biotechnology Index.
お知らせ • Jun 10GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion on June 9, 2026. Under the terms of the merger agreement, GSK will commence a tender offer to acquire all of Nuvalent's outstanding shares of Class A and Class B common stock at a purchase price of $124 per share in cash within 10 business days. The aggregate equity value of the transaction is estimated to be $10.6 billion (£8.0 billion). Net of cash acquired. Following the closing of the tender offer, GSK expects to acquire any remaining shares of Nuvalent through a second-step merger under Delaware law at the same price per share. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK's credit rating. The Merger Agreement also provides that Nuvalent must pay GlaxoSmithKline a termination fee of $350.5 million if (i) the Board determines to terminate the Merger Agreement in order to enter into a definitive agreement with respect to a superior proposal and Nuvalent so terminates or (ii) in the event that the Merger Agreement is terminated by GlaxoSmithKline following a change of recommendation by the Board. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent's outstanding shares of Class A common stock in the tender offer, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and approval of acquirer shareholders. The transaction is unanimously approved by both boards, and is expected to close in Q3, 2026. The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritization. Leerink Partners LLC acted as financial advisor for GSK plc. Citigroup Inc. acted as financial advisor for GSK plc. The team of Davis Polk & Wardwell LLP led by William J. Chudd, Daniel Brass, Saagar Kaul. Partner Jennifer S. Conway, David R. Bauer, Howard Shelanski, Suzanne Munck af Rosenschold and William A. Curran acted as legal advisor for GSK plc. Slaughter and May acted as legal advisor for GSK plc. Centerview Partners LLC acted as financial advisor and fairness opinion provider for Nuvalent, Inc. Emily J. Oldshue, Nicholas C.H. Roper, Renata J. Ferrari, Christa Sanchez, Megan R. Baca, Jimmy Chen, Ruchit Patel, Michael S. McFalls, Benjamin Rogers, Joshua Oyster and Leslie A. Thornton of Roper Ropes & Gray LLP acted as legal advisor for Nuvalent, Inc. Jefferies LLC acted as financial advisor for Nuvalent, Inc. Sidley Austin LLP acted as legal advisor for Nuvalent, Inc.